2009

Endocyte initiates phase 1 trial of EC0489 for treatment of refractory or metastatic solid tumors
--May 5, 2009

Endocyte to present multiple abstracts at the 100th annual meeting of the american association for cancer research (AACR)
--April 17, 2009

Endocyte announces positive interim results from phase II clinical trial of EC145 in patients with advanced non-small cell lung cancer (NSCLC)
-- March 24, 2009

Endocyte begins phase II clinical trial of EC145 for treatment of women with ovarian cancer
-- February 19, 2009

2008

Endocyte to Present at the BIO Investor Forum 2008
-- October 13, 2008

Endocyte Receives "Indiana Companies to Watch" Award
-- September 10, 2008

Endocyte Secures $15 Million Venture Debt Facility
-- January 25, 2008

Endocyte Announces Achievement of Milestone in Collaboration with Bristol-Myers Squibb
-- January 4, 2008

Endocyte to Present at the 26th Annual JPMorgan Healthcare Conference
-- January 3, 2008

2007

Endocyte Announces License Agreement with R&D Biopharmaceuticals for the Development of Targeted Tubulysin Chemotherapeutic Agents
-- December 21, 2007

Chandra Lovejoy joins Endocyte as Director of Regulatory Affairs
-- December 17, 2007

Endocyte secures $15 million in Series C-3 round of financing
-- March 23, 2007

2006

Endocyte awarded patent for vitamin-targeted imaging agent
-- November 29, 2006

Purdue honors faculty entrepreneurs for life-altering inventions
-- October 11, 2006

Michael A. Sherman Joins Endocyte as CFO
-- October 9, 2006

Keith E. Brauer Joins the Endocyte Board of Directors
-- September 12, 2006

Endocyte Announces Patent Issued to Enhance Cancer Targeting in Immunotherapy
-- May 16, 2006

Endocyte begins Phase 1 trial of EC145 for treatment of refractory solid tumors
-- April 20, 2006

Endocyte Signs Agreement with Bristol-Myers Squibb to Develop and Commercialize Folate-Targeted Chemotherapeutic Agents
-- January 5, 2006

2005

Endocyte Receives Notice of a U.S. Patent Allowance for a Targeted Immunotherapy Treatment
-- November 2, 2005

Richard Messmann join’s Endocyte’s executive management team
--July 13, 2005

Purdue anchors Indy's newest technology park, 3 companies move in
--April 26, 2005

Emory Researchers Awarded $1.6 Million to Study Common Type of Pituitary Tumor
--March 30, 2005

2004

Endocyte secures close to $23 million in Series C-2 round of financing
--December 06, 2004

Endocyte's research to reduce chemo's side effects receives state-federal dollars
--November 15, 2004

WL research 'triangle' sprouting walls, jobs
--August 15, 2004

Endocyte Inc. named a finalist for an Indiana Ernst & Young Entrepreneur of the Year 2004 Award
--May 10, 2004

Purdue Research Park to add 60,000 square feet of incubator space
--April 1, 2004

2003

Endocyte, Inc. honored with 2003 Indiana Growth 100 Award
--November 19, 2003

Endocyte Signs Clinical Trials Agreement with the National Cancer Institute for its FolateScan Product
--October 16, 2003

August Watanabe, M.D. joins board of directors at Endocyte
--September 5, 2003

Endocyte secures $15 million in Series C round of financing
--August 15, 2003

Endocyte begins first clinical trial with new metastatic cancer treatment
--May 9, 2003

Endocyte Selects eResearch Technology eResearch Network to Deliver Comprehensive Infrastructure
--May 6, 2003

New director of clinical operations joins Endocyte team
--January 31, 2003

2002

Endocyte enters third round of financing
--October 1, 2002

Researchers developing technology to outsmart metastasized cancers
--June 19, 2002

Endocyte signs license agreement with Galenica
--May 14, 2002

2001

Endocyte signs licensing agreement for Sangstat's Complexine Technology
--October 1, 2001

Endocyte Inc. secures $7.6 million in equity investments
--July 10, 2001

Cancer research firm among companies to benefit from grants
--February 22, 2001

1999

Endocyte, Inc. and National Cancer Institute announce agreement to develop vitamin based anticancer agents
--March 1, 1999